Literature DB >> 31782983

NNT-AS1 enhances bladder cancer cell growth by targeting miR-1301-3p/PODXL axis and activating Wnt pathway.

Yunxing Liu1, Guanlin Wu2,3.   

Abstract

As a tumor involved in the urinary system, bladder cancer (BC) seriously threatens human health. Emerging as crucial biomarkers, long noncoding RNAs (lncRNAs) play an important role in the regulation of many cancers. lncRNA NNT-AS1 has been studied in a series of cancers, whereas its role and potential molecular mechanism was poorly understood in BC. Here, we found that NNT-AS1 was upregulated in BC cells. Functionally, the silencing of NNT-AS1 inhibited cell proliferation, migration, invasion, and endothelial-mesenchymal transition. Furthermore, the apoptosis of BC cells was induced upon NNT-AS1 knockdown. Later, miR-1301-3p, the downstream gene of NNT-AS1, was found at a low level in BC cells. In addition, we found that miR-1301-3p targeted to PODXL. PODXL expression downregulated in NNT-AS1-silenced cells was restored by miR-1301-3p inhibition. Importantly, NNT-AS1 was discovered to activate Wnt pathway, and the treatment of LiCl recovered the repressive role of NNT-AS1 silencing in BC cell growth. Through restoration assays, we observed that PODXL overexpressing countervailed NNT-AS1 depletion-mediated suppression on BC cell growth and Wnt pathway. These data suggested that NNT-AS1 enhances BC cell growth and activates Wnt pathway by targeting miR-1301-3p/PODXL axis.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  NNT-AS1; PODXL; bladder cancer; miR-1301-3p

Mesh:

Substances:

Year:  2019        PMID: 31782983     DOI: 10.1002/nau.24238

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  9 in total

1.  Long non-coding RNA VPS9D1-AS1 promotes growth of colon adenocarcinoma by sponging miR-1301-3p and CLDN1.

Authors:  Wei Liu
Journal:  Hum Cell       Date:  2021-09-14       Impact factor: 4.374

2.  Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.

Authors:  Li Shan; Ye Lu; Cheng-Cheng Xiang; Xiaoli Zhu; Er-Dong Zuo; Xu Cheng
Journal:  J Immunol Res       Date:  2022-05-04       Impact factor: 4.493

Review 3.  Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis.

Authors:  Chunyu Zhang; Jiao Hu; Huihuang Li; Hongzhi Ma; Belaydi Othmane; Wenbiao Ren; Zhenglin Yi; Dongxu Qiu; Zhenyu Ou; Jinbo Chen; Xiongbing Zu
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

Review 4.  Aberrant Expression of miR-1301 in Human Cancer.

Authors:  Chenming Zhong; Yiyao Dong; Qiudan Zhang; Chunhui Yuan; Shiwei Duan
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

5.  LncRNA NNT-AS1 regulates proliferation, ECM accumulation and inflammation of human mesangial cells induced by high glucose through miR-214-5p/smad4.

Authors:  Zhuang Geng; Xiang Wang; Shiyuan Hao; Bingzi Dong; Yajing Huang; Yangang Wang; Lili Xu
Journal:  BMC Nephrol       Date:  2021-11-06       Impact factor: 2.388

6.  Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes.

Authors:  Linhui Wang; Yutao Wang; Jianfeng Wang; Luanfeng Li; Jianbin Bi
Journal:  J Immunol Res       Date:  2021-10-18       Impact factor: 4.818

7.  LncRNA-NNT-AS1 contributes to the progression of glioma by miR-582-5p/EZH2 axis.

Authors:  Tonglin Pan; Min Xue
Journal:  Cytotechnology       Date:  2021-04-28       Impact factor: 2.040

8.  Long non‑coding RNA 00858 knockdown alleviates bladder cancer via regulation of the miR‑3064‑5p/CTGF axis.

Authors:  Ji Huang; Qiu-Ming He; Qi Wu; Wei-Min Zhou; Chao Hao; Gong-Xian Wang; Xin-Hua Tu
Journal:  Oncol Rep       Date:  2021-06-16       Impact factor: 3.906

9.  Long non-coding RNA CRNDE regulates the growth and migration of prostate cancer cells by targeting microRNA-146a-5p.

Authors:  Dewang Fu; Li'e Zang; Zhaowei Li; Chenghui Fan; Huamao Jiang; Tongyi Men
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.